Details for New Drug Application (NDA): 211563
✉ Email this page to a colleague
The generic ingredient in DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE is dapagliflozin; metformin hydrochloride. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride profile page.
Summary for 211563
| Tradename: | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
| Applicant: | Alkem Labs Ltd |
| Ingredient: | dapagliflozin; metformin hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 211563
| Mechanism of Action | Sodium-Glucose Transporter 2 Inhibitors |
Suppliers and Packaging for NDA: 211563
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211563 | ANDA | Ascend Laboratories, LLC | 67877-619 | 67877-619-05 | 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67877-619-05) |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211563 | ANDA | Ascend Laboratories, LLC | 67877-619 | 67877-619-30 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67877-619-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 5MG;500MG | ||||
| Approval Date: | Apr 6, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 5MG;1GM | ||||
| Approval Date: | Apr 6, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 10MG;500MG | ||||
| Approval Date: | Apr 6, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
